# US 2008/0306086 A1 · Prolinamide derivatives as nk3 antagonists

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0306086 A1
- Document ID: US20080306086A1
- Status: Published application
- Kind: A1
- Application number: 12/129,718
- Filed: 2008-05-30
- Published: 2008-12-11
- Earliest claimed: 2007-06-07
- Assignees: Hoffmann-La Roche Inc.
- Inventors: Bo Han; Henner Knust; Matthias Nettekoven; Hasane Ratni; Xihan Wu
- Web page: https://patentgrep.com/patent/US20080306086A1

## CPC

- C07D 207/16: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/22: Anxiolytics
- A61P 25/24: Antidepressants
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 401/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 471/10: Spiro-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a compound of formula I wherein R2 R3, R4, R5, X, n, and o are as defined herein and to a pharmaceutically acceptable acid addition salt thereof which are high potential NK-3 receptor antagonists for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD).

## Claims

### Claim 1

A compound of formula I
wherein
R1 is hydrogen, halogen, lower alkyl, lower alkyl substituted by halogen, lower alkoxy, or lower alkoxy substituted by halogen;
R2 is hydrogen or lower alkyl;
R3 and R4 together with the N-atom to which they are attached form a non aromatic heterocyclic group, selected from
R5 is hydrogen or halogen;
R6 is phenyl, unsubstituted or substituted by cyano, halogen, lower alkyl, lower alkoxy, CF3, —(CH2)2O-lower alkyl, C(O)-lower alkyl or C(O)O-lower alkyl, or is pyridinyl, unsubstituted or substituted by CF3, or is —C(O)-phenyl;
R7 is hydrogen or lower alkoxy;
R8 is phenyl, lower alkyl or —C(O)O-lower alkyl;
R9 is hydrogen or S(O)2-lower alkyl;
R10 is hydrogen or cycloalkyl;
X is —CH2— or —C(O)—;
p is 1 or 2;
n is 1, 2 or 3; and
o is 1 or 2;
or a pharmaceutically acceptable acid addition salt thereof.

### Claim 2 (depends on 1)

A compound of claim 1, wherein X is —CH2.

### Claim 3 (depends on 2)

A compound of claim 2, wherein R3 and R4 together with the N-atom to which they are attached form a piperazine ring, which is substituted by R6.

### Claim 4 (depends on 3)

A compound of claim 3, wherein the R6 is phenyl substituted by cyano.

### Claim 5 (depends on 4)

A compound of claim 4, selected from the group consisting of
2-{4-[(2S,4S)-1-benzyl-4-(2,4-difluoro-benzylamino)-pyrrolidine-2-carbonyl]-piperazin-1-yl}-benzonitrile,
2-(4-{(2S,4S)-1-benzyl-4-[(3,5-bis-trifluoromethyl-benzyl)-methyl-amino]-pyrrolidine-2-carbonyl}-piperazin-1-yl)-benzonitrile,
2-{4-[(2S,4S)-1-benzyl-4-(3,5-dimethoxy-benzylamino)-pyrrolidine-2-carbonyl]-piperazin-1-yl}-benzonitrile,
2-{4-[(2S,4S)-1-benzyl-4-(2-trifluoromethyl-benzylamino)-pyrrolidine-2-carbonyl]-piperazin-1-yl}-benzonitrile,
2-{4-[(2S,4S)-1-benzyl-4-(2-chloro-5-trifluoromethyl-benzylamino)-pyrrolidine-2-carbonyl]-piperazin-1-yl}-benzonitrile,
2-{4-[(2S,4S)-1-benzyl-4-(3-chloro-benzylamino)-pyrrolidine-2-carbonyl]-piperazin-1-yl}-benzonitrile,
2-{4-[(2S,4S)-1-benzyl-4-(3-chloro-4-fluoro-benzylamino)-pyrrolidine-2-carbonyl]-piperazin-1-yl}-benzonitrile,
2-{4-[(2S,4S)-1-benzyl-4-(3,4-dichloro-benzylamino)-pyrrolidine-2-carbonyl]-piperazin-1-yl}-benzonitrile,
2-{4-[(2S,4S)-1-benzyl-4-(3-chloro-2-fluoro-benzylamino)-pyrrolidine-2-carbonyl]-piperazin-1-yl}-benzonitrile,
2-{4-[4-(2,4-difluoro-benzylamino)-1-(3-fluoro-benzyl)-pyrrolidine-2-carbonyl]-piperazin-lyl}-benzonitrile and
2-{4-[(2S,4R)-1-benzyl-4-(2,4-difluoro-benzylamino)-pyrrolidine-2-carbonyl]-piperazin-1-yl}-benzonitrile.

### Claim 6 (depends on 3)

A compound of claim 3, wherein the R6— is phenyl substituted by CF3.

### Claim 7 (depends on 6)

A compound of claim 6, selected from the group consisting of
[(2S,4S)-1-benzyl-4-(2,4-difluoro-benzylamino)-pyrrolidin-2-yl]-[4-(3-trifluoromethyl-phenyl)-piperazin-1-yl]-methanone,
{(2S,4S)-1-benzyl-4-[(3,5-bis-trifluoromethyl-benzyl)-methyl-amino]-pyrrolidin-2-yl}-[4-(3-trifluoromethyl-phenyl)-piperazin-1-yl]-methanone,
[(2S,4S)-4-[(3,5-bis-trifluoromethyl-benzyl)-methyl-amino]-1-(3-chloro-benzyl)-pyrrolidin-2-yl]-[4-(3-trifluoromethyl-phenyl)-piperazin-1-yl]-methanone and
[(2S,4R)-1-benzyl-4-(2,4-difluoro-benzylamino)-pyrrolidin-2-yl]-[4-(3-trifluoromethyl-phenyl)-piperazin-1-yl]-methanone.

### Claim 8 (depends on 3)

A compound of claim 3, wherein the R6— is phenyl substituted by halogen.

### Claim 9 (depends on 8)

A compound of claim 8, selected from the group consisting of
[(2S,4S)-1-benzyl-4-(2,4-difluoro-benzylamino)-pyrrolidin-2-yl]-[4-(4-fluoro-phenyl)-piperazin-1-yl]-methanone and
[(2S,4S)-1-benzyl-4-(2,4-difluoro-benzylamino)-pyrrolidin-2-yl]-[4-(2-chloro-phenyl)-piperazin-1-yl]-methanone.

### Claim 10 (depends on 3)

A compound of claim 3, wherein the R6— is phenyl unsubstituted or substituted by lower alkoxy.

### Claim 11 (depends on 10)

A compound of claim 10, selected from the group consisting of
[(2S,4S)-1-benzyl-4-(2,4-difluoro-benzylamino)-pyrrolidin-2-yl]-(4-phenyl-piperazin-1-yl)-methanone and
[(2S,4S)-1-benzyl-4-(2,4-difluoro-benzylamino)-pyrrolidin-2-yl]-[4-(2-methoxy-phenyl)-piperazin-1-yl]-methanone.

### Claim 12 (depends on 2)

A compounds of claim 2, wherein R3 and R4 together with the N-atom to which they are attached form the group 3,4-dihydro-1H-isoquinolin, substituted by R7.

### Claim 13 (depends on 12)

A compound of claim 12, wherein the compound is
[(2S,4S)-1-benzyl-4-(2,4-difluoro-benzylamino)-pyrrolidin-2-yl]-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-methanone.

### Claim 14 (depends on 1)

A compounds of claim 1, wherein X is —C(O)—.

### Claim 15 (depends on 14)

A compound of claim 14, selected from the group consisting of
N-{(3S,5S)-1-benzyl-5-[4-(2-cyano-phenyl)-piperazine-1-carbonyl]-pyrrolidin-3-yl}-2-chloro-benzamide,
N-{(3S,5S)-1-benzyl-5-[4-(2-cyano-phenyl)-piperazine-1-carbonyl]-pyrrolidin-3-yl}-3,5-dichloro-benzamide,
N-{(3S,5S)-1-benzyl-5-[4-(2-cyano-phenyl)-piperazine-1-carbonyl]-pyrrolidin-3-yl}-2-trifluoromethyl-benzamide and
N-{(3S,5S)-1-benzyl-5-[4-(2-cyano-phenyl)-piperazine-1-carbonyl]-pyrrolidin-3-yl}-2-methoxy-benzamide.

### Claim 16

A pharmaceutical composition comprising a therapeutically effective amount of a compound of formula I
wherein
R1 is hydrogen, halogen, lower alkyl, lower alkyl substituted by halogen, lower alkoxy, or lower alkoxy substituted by halogen;
R2 is hydrogen or lower alkyl;
R3 and R4 together with the N-atom to which they are attached form a non aromatic heterocyclic group, selected from
R5 is hydrogen or halogen;
R6 is phenyl, unsubstituted or substituted by cyano, halogen, lower alkyl, lower alkoxy, CF3, —(CH2)2O-lower alkyl, C(O)-lower alkyl or C(O)O-lower alkyl, or is pyridinyl, unsubstituted or substituted by CF3, or is —C(O)-phenyl;
R7 is hydrogen or lower alkoxy;
R8 is phenyl, lower alkyl or —C(O)O-lower alkyl;
R9 is hydrogen or S(O)2-lower alkyl;
R10 is hydrogen or cycloalkyl;
X is —CH2— or —C(O)
p is 1 or 2;
n is 1, 2 or 3; and
o is 1 or 2;
or a pharmaceutically acceptable acid addition salt thereof and a pharmaceutically acceptable carrier.
